Crenezumab (Alzheimer’s Disease)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer’s Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Strategic Competitor Assessment 40
6 Opportunity and Unmet Need 43
6.1 Unmet Needs Overview 43
6.1.1 Public Awareness 45
6.1.2 Specialized Institutions at Local Levels 46
6.1.3 Screening and Diagnosis 46
6.1.4 Early Intervention 47
6.1.5 Improved Clinical Trial Design 48
6.1.6 Effective Therapy 49
6.1.7 Behavioral Treatments 50
6.2 Gap Analysis 50
6.2.1 Disease Prevention 51
6.2.2 Diagnosis from Biomarkers 52
6.2.3 Behavioral Therapies 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Early-Stage Pipeline Assessment 54
7.3 AD Pipeline by Mechanism of Action 56
7.4 Enzymatic Processing 57
7.5 Immunization 58
7.6 Anti-Aggregation 58
7.7 “Me-Too” 59
7.8 Novel Therapeutic Approaches 60
7.9 Technology Trends Analytic Framework 60
7.10 Promising Drugs in Clinical Development 61
8 Crenezumab 63
8.1 Overview 63
8.2 Efficacy 64
8.3 Safety 64
8.4 Dosing and Formulation 65
8.5 Potential Clinical Positioning 65
8.6 Potential Commercial Positioning 65
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 66
8.9 Forecast 66
9 Appendix 67
9.1 Bibliography 67
9.2 Abbreviations 72
9.3 Methodology 75
9.4 Forecasting Methodology 75
9.4.1 Diagnosed AD patients 75
9.4.2 Percent Drug-treated Patients 76
9.4.3 General Pricing Assumptions 76
9.4.4 Generic Erosion 77
9.4.5 Pricing of Pipeline Agents 77
9.4.6 Alternate Scenarios 77
9.5 Physicians and Specialists Included in this Study 78
9.6 About the Authors 79
9.6.1 Author 79
9.6.2 Global Head of Healthcare 80
9.7 About GlobalData 81
9.8 Disclaimer 81